Crestor vs Repatha: Head-to-Head Efficacy Comparison

These Are Not Interchangeable Drugs

Rosuvastatin and evolocumab target the same lipid (LDL cholesterol) through entirely different biochemical pathways, and guidelines position them at different points in the treatment algorithm. A statin is almost always the starting point. A PCSK9 inhibitor enters the picture only when a statin alone, or a statin combined with ezetimibe, fails to drive LDL below the patient's risk-appropriate threshold.

Rosuvastatin inhibits HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step of cholesterol synthesis in the liver 1. By blocking production, the liver compensates by pulling more LDL particles from the bloodstream. A 20 mg dose typically lowers LDL by 45-52%, and the maximum 40 mg dose can push that closer to 55% in some patients 2.

Evolocumab works downstream. It is a fully human monoclonal antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that would otherwise degrade LDL receptors on liver cells 3. Blocking PCSK9 means more LDL receptors survive on the hepatocyte surface, pulling even more LDL out of the blood. Because the two mechanisms are complementary, combining a statin with evolocumab produces additive LDL lowering that neither drug achieves alone.

The 2018 ACC/AHA Cholesterol Clinical Practice Guideline states: "In patients with clinical ASCVD who are judged to be very high risk and considered for PCSK9 inhibitor therapy, maximally tolerated LDL-C lowering therapy should include maximally tolerated statin therapy and ezetimibe" 4. That language makes clear these drugs occupy sequential tiers, not competing slots.

JUPITER Trial: What Rosuvastatin Proved

The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) enrolled 17,802 apparently healthy men and women with LDL cholesterol below 130 mg/dL but high-sensitivity C-reactive protein (hsCRP) of 2.0 mg/L or higher 1. Participants received rosuvastatin 20 mg daily or placebo. The data safety monitoring board stopped the trial early, at a median follow-up of 1.9 years, because the treatment group showed a 44% reduction in the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or confirmed cardiovascular death (HR 0.56, 95% CI 0.46-0.69).

That is a large effect size. Rosuvastatin cut LDL cholesterol by 50%, from a median of 108 mg/dL to 55 mg/dL, and dropped hsCRP by 37%. The trial established that statin therapy produces measurable cardiovascular benefit even in patients who would not have qualified for treatment under older, LDL-threshold-only guidelines.

One limitation: JUPITER tested rosuvastatin against placebo, not against another active therapy. Its 44% relative risk reduction reflects the gap between statin and nothing, a comparison that does not apply to patients already taking a statin who are considering whether to add evolocumab.

FOURIER Trial: What Evolocumab Proved

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) already receiving statin therapy 3. Patients were randomized to evolocumab (140 mg every two weeks or 420 mg monthly, patient's choice) or matching placebo.

At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina) by 15% (HR 0.85, 95% CI 0.79-0.92, P<0.001). The key secondary endpoint of cardiovascular death, MI, or stroke, a harder outcome measure, dropped by 20% (HR 0.80, 95% CI 0.73-0.88) 3.

LDL fell from a median baseline of 92 mg/dL to 30 mg/dL, a 59% reduction layered on top of the statin's contribution. FOURIER demonstrated that pushing LDL well below 70 mg/dL (and even below 40 mg/dL) produced additional atherosclerotic event reduction without a safety signal at these very low levels.

The 15% relative risk reduction in FOURIER may look smaller than JUPITER's 44%. That comparison is misleading. FOURIER measured the incremental benefit of adding evolocumab to a statin, while JUPITER measured rosuvastatin against no lipid-lowering treatment at all. The correct interpretation: evolocumab delivers meaningful additional protection once a statin has already done its work.

LDL Reduction: Putting the Numbers Side by Side

Raw LDL-lowering potency is the simplest comparison. Rosuvastatin 40 mg monotherapy lowers LDL by approximately 52-55% from an untreated baseline 2. Evolocumab, when added to maximally tolerated statin therapy, drops LDL by another 59% from the already-reduced on-statin level 3.

A worked example clarifies. A patient with an untreated LDL of 180 mg/dL starts rosuvastatin 40 mg and reaches roughly 85 mg/dL. Adding evolocumab drops that 85 mg/dL by 59%, landing around 35 mg/dL. The statin does the heavy lifting first; the PCSK9 inhibitor polishes the remainder to a level that was pharmacologically unreachable before this drug class existed.

The GLAGOV trial (N=968) confirmed that this degree of LDL lowering translates into measurable plaque regression. Patients receiving evolocumab on top of statin therapy achieved a mean percent atheroma volume reduction of 0.95%, compared to a 0.05% increase in the statin-alone group (P<0.001) 5. The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias recommend LDL goals of <55 mg/dL for very high-risk patients and <40 mg/dL for those with a second vascular event within two years 6. Reaching those aggressive targets almost always requires combination therapy.

Who Should Take Which Drug (and When Both Are Needed)

Prescribing decisions follow a stepwise algorithm, not a one-or-the-other choice. The 2018 ACC/AHA guideline establishes a clear hierarchy 4.

Step 1: Start a high-intensity statin. Rosuvastatin 20-40 mg or atorvastatin 40-80 mg. This is first-line for any patient with clinical ASCVD, LDL ≥190 mg/dL, or a 10-year ASCVD risk high enough to warrant pharmacotherapy.

Step 2: Reassess LDL after 4-12 weeks. If LDL remains above the patient's target (typically <70 mg/dL for secondary prevention, <55 mg/dL under ESC/EAS for very high risk), add ezetimibe 10 mg.

Step 3: If LDL still misses goal on maximally tolerated statin plus ezetimibe, consider a PCSK9 inhibitor. Evolocumab 140 mg every two weeks or alirocumab 75-150 mg every two weeks. This step also applies to patients with statin intolerance who cannot reach goal with ezetimibe alone.

Step 4: Special populations. Patients with familial hypercholesterolemia (FH) may need a PCSK9 inhibitor earlier in the algorithm. The RUTHERFORD-2 trial showed evolocumab reduced LDL by 59-61% in heterozygous FH patients already on statin therapy 7.

Dr. Robert Giugliano, lead author of FOURIER and a cardiologist at Brigham and Women's Hospital, noted in the trial publication: "These data indicate that inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter and reduced the risk of cardiovascular events" 3.

The practical takeaway: rosuvastatin and evolocumab are partners, not alternatives. Asking "which is better" is like asking whether the foundation or the roof matters more. Both do different jobs in a lipid-lowering strategy.

Side Effects and Tolerability

Rosuvastatin's side-effect profile is well-characterized across decades of post-marketing surveillance. Myalgia (muscle pain without CPK elevation) affects 5-10% of patients on high-intensity statins and is the primary reason patients discontinue or reduce doses 8. True rhabdomyolysis is rare, occurring in approximately 1-3 per 100,000 patient-years. Hepatotoxicity (ALT elevation above three times the upper limit of normal) occurs in under 1% of patients. New-onset diabetes was observed in JUPITER at a rate of 270 cases vs 216 in placebo (HR 1.25), a finding replicated across other statin trials and considered a class effect 1.

Evolocumab's tolerability profile has been notably clean. In FOURIER, injection-site reactions occurred in 2.1% of evolocumab patients vs 1.6% on placebo 3. Neurocognitive adverse events showed no significant difference between groups. The EBBINGHAUS sub-study (N=1,974), which formally tested cognition using the Cambridge Neuropsychological Test Automated Battery, found no association between very low LDL levels and cognitive decline over a median of 19 months 9.

PCSK9 inhibitors carry no muscle toxicity signal. This makes evolocumab a viable option for patients with genuine statin intolerance who still need aggressive LDL lowering. Neutralizing antibodies to evolocumab were detected in 0.3% of treated patients, with no apparent impact on efficacy or safety.

The tradeoff is route of administration. A daily pill is simple. A biweekly subcutaneous injection using an autoinjector requires more patient education and comfort with self-injection, though adherence rates in clinical practice have been reasonable.

Cost and Insurance Access

Generic rosuvastatin, available since 2016, costs $5-30 per month at most pharmacies even without insurance. Brand Crestor, if prescribed by name, remains more expensive but is rarely necessary. The low cost makes rosuvastatin one of the most cost-effective interventions in cardiovascular medicine.

Evolocumab tells a different story. The current list price sits at approximately $450-600 per month 10. Amgen reduced the price from its original $14,100 per year in response to cost-effectiveness analyses and payer pushback. Most commercial insurers cover evolocumab but require prior authorization demonstrating that the patient has tried a maximally tolerated statin, added ezetimibe, and still has LDL above goal. Some plans require a specific LDL threshold (often ≥70 mg/dL on combination oral therapy) or documentation of statin intolerance confirmed by rechallenge.

The cost gap between these two drugs is not a minor detail. It shapes who receives PCSK9 inhibitor therapy in practice. An analysis from the ACC's NCDR PINNACLE Registry showed that among patients potentially eligible for PCSK9 inhibitors, only 2.1% were prescribed one by 2017, with disparities across race, sex, and insurance type 11.

Manufacturer patient assistance programs can reduce or eliminate co-pays for qualifying patients. Amgen's co-pay card program and patient assistance foundation cover a substantial portion of commercially insured and uninsured patients, respectively.

The Bottom Line on Choosing Between or Combining These Drugs

No randomized trial has tested rosuvastatin against evolocumab head-to-head as monotherapies for cardiovascular outcomes. That trial would not answer a clinically useful question because the drugs occupy different rungs of the treatment algorithm. The real clinical decision is not "one or the other" but "how far down the ladder does this patient need to go?"

For primary prevention in patients without ASCVD, rosuvastatin alone (or another high-intensity statin) remains the standard. For secondary prevention in patients with established ASCVD whose LDL stays above 70 mg/dL despite a statin and ezetimibe, evolocumab offers a 15-20% further MACE reduction with a favorable safety profile 3. For patients with heterozygous FH or recurrent cardiovascular events, the combination of high-intensity statin plus PCSK9 inhibitor can bring LDL below 30 mg/dL, a level associated with plaque regression in GLAGOV 5.

Start with rosuvastatin. Add ezetimibe if needed. Add evolocumab when the first two are not enough. That sequence, validated by multiple guideline committees and outcome trials, gives patients the highest probability of reaching the LDL goal associated with the lowest residual cardiovascular risk.